While significant progress has been made in treating certain forms of malignancy in recent decades, ovarian cancer (OC) remains a disease with a considerably poor prognosis. Ovarian cancer is typically diagnosed at stages III-IV; at this stage, the 5-year survival rates are approximately 27% and 16%, respectively. This is why there is an urgent need to discover new methods for the early detection of OC. We first evaluated OC screening in conjunction with ultrasound studies between 2001 and 2003. We found that this screening program improved survival rates. However, since then, transvaginal ultrasound studies have become widespread, and methods for interpreting ultrasound data have been updated. A new NLS study system with a digital trigger sensor was created – this allowed us to apply continuous spiral scanning during the screening process. New methods were introduced; 3D visualization of study results was also introduced. All these changes led to a significant improvement in study accuracy.

Data from Meta Hunter is playing an increasingly important role in medicine, clearly transforming modern medicine and poised to participate in more treatments in the future, bringing greater assistance to the medical community and ultimately leading to greater health and well-being for people!